{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T17:28:42Z","timestamp":1771608522568,"version":"3.50.1"},"reference-count":72,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.heliyon.2022.e10586","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T08:52:53Z","timestamp":1662972773000},"page":"e10586","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Roadmap for new practitioners to navigate the multiple myeloma landscape"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1741-3739","authenticated-orcid":false,"given":"Tiffany","family":"Tam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyn","family":"Lozoya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayley","family":"Heers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Andrew Allred","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2022.e10586_bib1","series-title":"Williams Hematology, 9e","author":"Kaushansky","year":"2015"},{"issue":"3","key":"10.1016\/j.heliyon.2022.e10586_bib5","doi-asserted-by":"crossref","first-page":"9054","DOI":"10.4081\/hr.2020.9054","article-title":"The molecular pathogenesis of multiple myeloma","volume":"12","author":"Bolli","year":"2020","journal-title":"Hematol. Rep."},{"key":"10.1016\/j.heliyon.2022.e10586_bib2","series-title":"Multiple Myeloma. Version 5","year":"2022"},{"key":"10.1016\/j.heliyon.2022.e10586_bib3","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.heliyon.2022.e10586_bib4","series-title":"Handbook of Hematologic Malignancies","author":"Sallman","year":"2017"},{"issue":"2","key":"10.1016\/j.heliyon.2022.e10586_bib6","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/leu.2011.204","article-title":"A\u00a0novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX tria","volume":"26","author":"Boyd","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.heliyon.2022.e10586_bib60","series-title":"Thalomid (thalidomide) [product monograph]","year":"2021"},{"key":"10.1016\/j.heliyon.2022.e10586_bib61","series-title":"Revlimid (Lenalidomide) [prescribing Information]","year":"2021"},{"key":"10.1016\/j.heliyon.2022.e10586_bib62","series-title":"Pomalyst (Pomalidomide) [prescribing Information]","year":"2021"},{"key":"10.1016\/j.heliyon.2022.e10586_bib17","year":"2021"},{"key":"10.1016\/j.heliyon.2022.e10586_bib63","series-title":"Bortezomib [prescribing Information]","year":"2022"},{"key":"10.1016\/j.heliyon.2022.e10586_bib64","series-title":"Ninlaro (ixazomib) [prescribing information]","year":"2022"},{"key":"10.1016\/j.heliyon.2022.e10586_bib65","series-title":"Empliciti (Elotuzumab) [prescribing Information]","year":"2022"},{"key":"10.1016\/j.heliyon.2022.e10586_bib66","series-title":"Darzalex (daratumumab) [prescribing information]","year":"2022"},{"key":"10.1016\/j.heliyon.2022.e10586_bib67","series-title":"Darzalex Faspro (daratumumab\/hyaluronidase) [prescribing information]","year":"2022"},{"key":"10.1016\/j.heliyon.2022.e10586_bib68","series-title":"Sarclisa (isatuximab) [prescribing information]","year":"2021"},{"key":"10.1016\/j.heliyon.2022.e10586_bib69","series-title":"Blenrep (Belantamab Mafodotin) [prescribing Information]","year":"2022"},{"key":"10.1016\/j.heliyon.2022.e10586_bib32","series-title":"Xpovio (selinexor) [prescribing information]","year":"2021"},{"key":"10.1016\/j.heliyon.2022.e10586_bib70","series-title":"Venclexta (Venetoclax) [product Monograph]","year":"2022"},{"issue":"1","key":"10.1016\/j.heliyon.2022.e10586_bib7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00277-018-3465-8","article-title":"Glucocorticoids in multiple myeloma: past, present, and future","volume":"98","author":"Burwick","year":"2019","journal-title":"Ann. Hematol."},{"issue":"1","key":"10.1016\/j.heliyon.2022.e10586_bib8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: An open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.heliyon.2022.e10586_bib9","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40265-017-0689-1","article-title":"Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience","volume":"77","author":"Holstein","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.heliyon.2022.e10586_bib10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanisms of action of immunomodulatory drugs (IMiDs) in multiple myeloma","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.heliyon.2022.e10586_bib11","series-title":"Celgene REMS Program","year":"2022"},{"issue":"11","key":"10.1016\/j.heliyon.2022.e10586_bib12","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-11-0433","article-title":"Mechanism of action of proteosome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma","volume":"10","author":"Hideshima","year":"2011","journal-title":"Mol. Cancer Therapeut."},{"issue":"12, suppl 2","key":"10.1016\/j.heliyon.2022.e10586_bib13","article-title":"Comparative mechanisms of action of proteosome inhibitors","volume":"25","author":"Wang","year":"2011","journal-title":"Oncology"},{"issue":"12","key":"10.1016\/j.heliyon.2022.e10586_bib14","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.3324\/haematol.13285","article-title":"Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma","volume":"93","author":"Moreau","year":"2008","journal-title":"Haematologica"},{"issue":"16","key":"10.1016\/j.heliyon.2022.e10586_bib15","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1182\/blood-2010-02-271676","article-title":"Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma","volume":"115","author":"Reeder","year":"2010","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.heliyon.2022.e10586_bib16","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S1470-2045(18)30354-1","article-title":"Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (ARROW): interim analysis results of a randomized, phase 3 study","volume":"19","author":"Moreau","year":"2018","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.heliyon.2022.e10586_bib18","doi-asserted-by":"crossref","first-page":"p1317","DOI":"10.1016\/S1470-2045(20)30452-6","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol."},{"issue":"10168","key":"10.1016\/j.heliyon.2022.e10586_bib19","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(18)33003-4","article-title":"Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"393","author":"Dimopoulos","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2022.e10586_bib20","doi-asserted-by":"crossref","first-page":"7891","DOI":"10.2147\/CMAR.S212526","article-title":"Evaluating daratumumab in the treatment of multiple myeloma: safety, efficacy and place in therapy","volume":"12","author":"Dima","year":"2020","journal-title":"Cancer Manag. Res."},{"issue":"10","key":"10.1016\/j.heliyon.2022.e10586_bib21","doi-asserted-by":"crossref","first-page":"e777","DOI":"10.1016\/j.clml.2020.05.024","article-title":"Evaluation of montelukast for the prevention of infusion-related reactions with daratumumab","volume":"20","author":"Moore","year":"2020","journal-title":"Clin. Lymphoma, Myeloma & Leukemia"},{"issue":"5","key":"10.1016\/j.heliyon.2022.e10586_bib22","doi-asserted-by":"crossref","first-page":"e370","DOI":"10.1016\/S2352-3026(20)30070-3","article-title":"Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial","volume":"7","author":"Mateos","year":"2020","journal-title":"The Lancet. Haematology"},{"key":"10.1016\/j.heliyon.2022.e10586_bib23","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.3389\/fimmu.2018.02616","article-title":"Blood transfusion management for patients treated with anti-CD38 monoclonal antibodies","volume":"9","author":"Lancman","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2022.e10586_bib24","first-page":"327","article-title":"Overcoming drug interference in transfusion testing: a spotlight on daratumumab","volume":"12","author":"Nedumcheril","year":"2021","journal-title":"Hematol. Res. Rev."},{"key":"10.1016\/j.heliyon.2022.e10586_bib25","doi-asserted-by":"crossref","first-page":"5813","DOI":"10.2147\/OTT.S174640","article-title":"Update on elotuzumab for the treatment of relapsed\/refractory multiple myeloma: patients' selection and perspective","volume":"12","author":"Trudel","year":"2019","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.heliyon.2022.e10586_bib26","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2018","journal-title":"NEJM"},{"issue":"5","key":"10.1016\/j.heliyon.2022.e10586_bib27","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s11523-021-00827-0","article-title":"A\u00a0review of its use in multiple myeloma","volume":"16","author":"Isatuximab","year":"2021","journal-title":"Targeted Oncol."},{"issue":"5","key":"10.1016\/j.heliyon.2022.e10586_bib28","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41408-021-00478-4","article-title":"A\u00a0phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab","volume":"11","author":"Mikhael","year":"2021","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.heliyon.2022.e10586_bib29","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3390\/curroncol28010063","article-title":"Belantamab mafodotin to treat multiple myeloma: a comprehensive review of disease, drug efficacy and side effects","volume":"28","author":"Lassiter","year":"2021","journal-title":"Curr. Oncol."},{"issue":"suppl","key":"10.1016\/j.heliyon.2022.e10586_bib30","article-title":"DREAMM-6 safety, tolerability and clinical activity of belantamab mafodotin (Belamaf) in combination with bortezomib\/dexamethasone (BorDex) in relapsed\/refractory multiple myeloma (RRMM)","volume":"38","author":"Nooka","year":"2020","journal-title":"J.\u00a0Clin. Oncol."},{"issue":"5","key":"10.1016\/j.heliyon.2022.e10586_bib31","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.clml.2018.03.003","article-title":"Clinical implications of targeting XPO1-mediated nuclear export in multiple myeloma","volume":"18","author":"Gandhi","year":"2018","journal-title":"Clin. Lymphoma, Myeloma & Leukemia"},{"issue":"8","key":"10.1016\/j.heliyon.2022.e10586_bib33","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral selinexor-dexamethasone for triple-class refractory multiple myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"NEJM"},{"issue":"12","key":"10.1016\/j.heliyon.2022.e10586_bib34","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.heliyon.2022.e10586_bib35","first-page":"422","article-title":"Long-term outcomes after autologous stem cell transplantation for multiple myeloma","volume":"4","author":"Nishimura","year":"2020","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.heliyon.2022.e10586_bib36","doi-asserted-by":"crossref","first-page":"6063","DOI":"10.1182\/blood-2011-02-297325","article-title":"International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation","volume":"117","author":"Cavo","year":"2011","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.heliyon.2022.e10586_bib37","first-page":"5988","article-title":"A\u00a0large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.heliyon.2022.e10586_bib38","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1182\/bloodadvances.2018017186","article-title":"Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM","volume":"2","author":"Jagannath","year":"2018","journal-title":"Blood advances"},{"issue":"1","key":"10.1016\/j.heliyon.2022.e10586_bib39","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40487-021-00143-7","article-title":"Post-transplant maintenance treatment options in multiple myeloma","volume":"9","author":"Karam","year":"2021","journal-title":"Oncology and therapy"},{"key":"10.1016\/j.heliyon.2022.e10586_bib40","series-title":"Abecma (Idecabtagene Vicleucel) [prescribing Information]","year":"2021"},{"key":"10.1016\/j.heliyon.2022.e10586_bib41","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"NEJM"},{"key":"10.1016\/j.heliyon.2022.e10586_bib42","series-title":"Carvykti (Ciltacabtagene Autoleucel) [prescribing Information]","year":"2022"},{"issue":"15","key":"10.1016\/j.heliyon.2022.e10586_bib43","article-title":"CARTITUDE-2: efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy","volume":"39","author":"Agha","year":"2021","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.heliyon.2022.e10586_bib45","series-title":"Prevention and Treatment of Cancer-Related Infections","year":"2021"},{"issue":"30","key":"10.1016\/j.heliyon.2022.e10586_bib46","first-page":"3042","article-title":"Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update","volume":"3","author":"Taplitz","year":"2018","journal-title":"J.\u00a0Clin. Oncol."},{"issue":"12","key":"10.1016\/j.heliyon.2022.e10586_bib47","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S1470-2045(19)30506-6","article-title":"Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial","volume":"20","author":"Drayson","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.heliyon.2022.e10586_bib48","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1200\/JCO.20.01757","article-title":"Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update","volume":"38","author":"Hwang","year":"2020","journal-title":"J.\u00a0Clin. Oncol."},{"issue":"4","key":"10.1016\/j.heliyon.2022.e10586_bib49","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3324\/haematol.2019.230011","article-title":"Fractures and survival in multiple myeloma: results from a population-based study","volume":"105","author":"Thorsteinsdottir","year":"2020","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.heliyon.2022.e10586_bib50","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 trial","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.heliyon.2022.e10586_bib51","series-title":"Aclasta (zoledronic acid) [product monograph]","year":"2017"},{"key":"10.1016\/j.heliyon.2022.e10586_bib52","series-title":"Xgeva (Denosumab) [prescribing Information]","year":"2020"},{"issue":"1","key":"10.1016\/j.heliyon.2022.e10586_bib53","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2016.19425","article-title":"Effect of longer-interval vs. standard dosing of zoledronic acid on skeletal events in patients with bone metastases","volume":"317","author":"Himelstein","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.heliyon.2022.e10586_bib54","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jobcr.2012.11.001","article-title":"Dental complications and management of patients on bisphosphonate therapy: a review article","volume":"3","author":"Kalra","year":"2013","journal-title":"J.\u00a0Oral Biol. Craniofac. Res."},{"key":"10.1016\/j.heliyon.2022.e10586_bib55","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.14219\/jada.archive.2006.0355","article-title":"Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations","volume":"137","author":"Edwards","year":"2006","journal-title":"JADA (J. Am. Dent. Assoc.)"},{"issue":"1","key":"10.1016\/j.heliyon.2022.e10586_bib56","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/annonc\/mdr039","article-title":"Impact of dental care in the prevention of bisphosphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience","volume":"23","author":"Vandone","year":"2012","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.heliyon.2022.e10586_bib57","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/bjh.15684","article-title":"Venous thromboembolism in multiple myeloma - choice of prophylaxis, role of direct oral anticoagulants and special considerations","volume":"183","author":"Swan","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"79","key":"10.1016\/j.heliyon.2022.e10586_bib58","article-title":"Daratumumab (DARA) plust lenalidmide, bortezomib, and dexamethasone (RVD) in patients (Pts) with transplant-eligible newly diagnosed multiple myeloma (NDMM): updated analysis of Griffin after 24 months of maintenance","volume":"138","author":"Laubach","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2022.e10586_bib59","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood-2021-145097","article-title":"Addition of isatuximab to lenalidomide, bortezomib and dexamethasone as induction therapy for newly-diagnosed, transplant-eligible multiple myeloma patients: the phase III GMMG-HD7 trial","volume":"138","author":"Goldschmidt","year":"2021","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.heliyon.2022.e10586_bib71","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2022.e10586_bib72","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/hematology.2021000230","article-title":"Minimal residual disease in multiple myeloma: why, when, where","volume":"1","author":"Yee","year":"2021","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.heliyon.2022.e10586_bib73","series-title":"Health-related Quality of Life in Patients with Relapsed\/refractory Multiple Myeloma (RRMM) Treated with Teclistamab, a B-Cell Maturation Antigen (BCMA) X CD3 Bispecific Antibody: Patient-Reported Outcomes in MajesTEC-1. 2022 ASCO Annual Meeting","author":"Martin","year":"2022"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844022018746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844022018746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T09:46:19Z","timestamp":1767087979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844022018746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":72,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S2405844022018746"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2022.e10586","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Roadmap for new practitioners to navigate the multiple myeloma landscape","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2022.e10586","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e10586"}}